About NEUROPATHIX
NEUROPATHIX is a company based in Doylestown (United States) founded in 2010 by Thoma Kikis. The company has 7 employees as of December 31, 2020. NEUROPATHIX offers products and services including KLS-13019 and Patented NCEs. NEUROPATHIX operates in a competitive market with competitors including GW Pharma, IGC Pharma, MIRA Pharmaceuticals, Agrithera and Avata Biosciences, among others.
- Headquarter Doylestown, United States
- Employees 7 as on 31 Dec, 2020
- Founders Thoma Kikis
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neuropathix, Inc.
-
Annual Revenue
$183.48 K (USD)0as on Dec 31, 2021
-
Net Profit
-$3.56 M (USD)22as on Dec 31, 2021
-
EBITDA
-$2.94 M (USD)34as on Dec 31, 2021
-
Latest Funding Round
$1.21 M (USD), Post-IPO
Feb 23, 2021
-
Investors
Not available
-
Employee Count
7
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NEUROPATHIX
NEUROPATHIX offers a comprehensive portfolio of products and services, including KLS-13019 and Patented NCEs.
Cannabinoid-inspired molecule for treating inflammation and pain effectively.
Novel agents targeting neurological disorders and oxidative stress.
People of NEUROPATHIX
Unlock access to complete
Unlock access to complete
Funding Insights of NEUROPATHIX
Investments & Acquisitions by NEUROPATHIX
Investment portfolio details for NEUROPATHIX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NEUROPATHIX
Detailed financials for NEUROPATHIX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neuropathix Comparisons
Peer comparison for NEUROPATHIX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NEUROPATHIX
NEUROPATHIX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GW Pharma, IGC Pharma, MIRA Pharmaceuticals, Agrithera and Avata Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy
|
|
| Locked | Locked | Locked |
Pharmaceutical products targeting neurological disorders like Alzheimer's are developed.
|
|
| Locked | Locked | Locked |
Cannabinoid-based therapeutics for chronic pain and anxiety are developed.
|
|
| Locked | Locked | Locked |
Cannabis-based therapeutics are developed for pain and neurological disorders.
|
|
| Locked | Locked | Locked |
Develops synthetic cannabinoids for epilepsy and schizophrenia treatments through innovative formulations.
|
Detailed competitors of NEUROPATHIX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neuropathix
Complete news archive for NEUROPATHIX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NEUROPATHIX
NEUROPATHIX was founded in 2010 and raised its 1st funding round 11 years after it was founded.
NEUROPATHIX is headquartered in Doylestown, United States. It is registered at Doylestown, Pennsylvania, United States.
Dean Petkanas is the current CEO of NEUROPATHIX.
As of Dec 31, 2020, the latest employee count at NEUROPATHIX is 7.
Annual revenue of NEUROPATHIX is $183.48K as on Dec 31, 2021.
Therapeutics targeting inflammation, neurodegeneration, oxidative stress, and neuropathic pain are developed by NEUROPATHIX, founded in 2010 and based in Doylestown, United States. Preclinical drug discovery and development of synthetic cannabidiol-inspired molecules form the core operations within the biotechnology sector. Research efforts address neurodegenerative diseases, oxidative stress conditions, and neuropathic pain disorders through a dedicated product platform.
NEUROPATHIX's top competitors include IGC Pharma, MIRA Pharmaceuticals and GW Pharma.
NEUROPATHIX offers KLS-13019 and Patented NCEs.